Kidney

, Volume 19, Issue 2, pp 66–72 | Cite as

Relation Between Thyroid Hormones and Insulin Resistance in Hemodialysis Patients

Article
  • 38 Downloads

Abstract

Insulin resistance (IR) is a common problem in patients with ESRD on regular HD, and it is related to many complications, including cardiovascular complications, the major killer in these patients. Disorders of thyroid function are common in patients with ESRD. Many factors have been claimed to contribute to IR in HD patients. Our aim is to study the relations between thyroid hormones and IR in HD patients for better understanding and management of IR. The study involved 35 patients with ESRD under regular HD (group 1) and 20 normal control subjects (group 2). All of them underwent complete history taking and clinical examination: biochemical and hematological, thyroid hormones TSH, free T3 (FT3) and free T4 (FT4), and insulin resistance using the homeostasis model assessment (HOMA-IR). Patients with DM and those with known thyroid disorders were excluded from the study. Comparing HD patients and normal control subjects shows significant differences as regards FT3 (p = 0.04) 33.58 ± 12.14 vs. 40.63 ± 11.27 pg/l, respectively; TSH (p = 0.03) 3.29 ± 3.83 vs. 1.80 ± 0.88 mu/l, respectively; fasting insulin level (p < 0.001) 30.1 ± 6.05 vs. 10.68 ± 2.77 mu/ml, respectively; HOMA (p < 0.001) 6.72 ± 1.41 vs. 2.4 ± 0.67, respectively. There is no significant difference as regards FT4 (p = 0.36) 15.17 ± 6.72 vs. 16.35 ± 2.66 pmol/l, respectively. Bivariate correlation in HD patients shows HOMA IR correlates with FT3 (p < 0.001), FT4 (p < 0.001), TSH (p < 0.001), HDL (p < 0.001), and hematocrit (p < 0.001). No correlations were found with BMI, age, total cholesterol, LDL, or triglycerides. Linear regression analysis showed HOMA-IR was independently determined by HDL (p = 0.04), hematocrit (p = 0.02), and TSH (p = 0.008). IR is very common in HD patients. There is a close correlation between IR and thyroid hormones. TSH, HDL, and hematocrit levels independently determine IR. Regular follow-up of these factors is necessary for proper management of IR.

Keywords

Insulin resistance Thyroid hormones Hemodialysis End-stage renal disease 

Abbreviations

IR

insulin resistance

ESRD

end-stage renal disease

HD

hemodialysis

FT3

free T3

FT4

free T4

HOMA-IR

homeostasis model assessment

References

  1. 1.
    Linder A, Charra B, Sherpard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974;290:697–701.Google Scholar
  2. 2.
    Mak RHK. Renal disease, insulin resistance and glucose intolerance. Diabetes. 1994;2:19–28.Google Scholar
  3. 3.
    Ikeda T, Gomi T, Hirawa N, Sakurai J, Yoshikawa N. Improvement of insulin sensitivity contributes to blood pressure reduction after weight loss in hypertensive subjects with obesity. Hypertension. 1996;27:1180–6.PubMedGoogle Scholar
  4. 4.
    Mak RHK, DeFronzo RA. Glucose and insulin metabolism in uremia. Nephron. 1992;61:377–82.CrossRefPubMedGoogle Scholar
  5. 5.
    De pergola G, Ciampolillo A, Paolotti S, Trerotoli P, Giorgino R. Free triiodothyronine and thyroid stimulating hormone are directly associated with waist circumference, independently of insulin resistance, metabolic parameters and blood pressure in overweight and obese women. Clin Endocrinol. 2007;67(2):265–9.CrossRefGoogle Scholar
  6. 6.
    Bakker SJ, Ter Maaten JC, et al. The relationship between thyrotropin and low-density lipoprotein cholesterol is modified by insulin sensitivity in healthy euthyroid subjects. J Clin Endocrinol Metab. 2001;86:1206–11.CrossRefPubMedGoogle Scholar
  7. 7.
    Singh PA, Bobby Z, Selvaraj N, Vinayagamoorthi R. An evaluation of thyroid hormone status and oxidative stress in undialyzed chronic renal failure patients. Indian J Physiol Pharmacol. 2006;50:279–84.PubMedGoogle Scholar
  8. 8.
    Kaptein EM. Thyroid hormone metabolism and thyroid diseases in chronic renal failure. Endocr Rev. 1996;17:45–63.PubMedGoogle Scholar
  9. 9.
    Iglesias P, Dı´ez JJ. Thyroid dysfunction and kidney disease. Eur J Endocrinol. 2009;160:503–15.CrossRefPubMedGoogle Scholar
  10. 10.
    Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998;21:2191–2.CrossRefPubMedGoogle Scholar
  11. 11.
    Shoji T, Emoto M, YN. HOMA index to assess insulin resistance in renal failure patients. Nephron. 2001;89:348-9.Google Scholar
  12. 12.
    Shinohara K, Shoji T, et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol. 2002;13:1894–900.CrossRefPubMedGoogle Scholar
  13. 13.
    Despres JP, Lamarche B, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334:952–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Sit D, Kadiroglu AK, Kayabasi H, Yilmaz ME. The prevalence of insulin resistance in nondiabetic nonobese patients with chronic kidney disease. Adv Ther. 2006;23:988–98.CrossRefPubMedGoogle Scholar
  15. 15.
    Chen HH, Wu CJ, et al. Metabolic syndrome is associated with severe coronary artery disease and poor cardiac outcome in end-stage renal disease patients with acute coronary syndrome. Coron Artery Dis. 2006;17:593–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Stefanovi V, Nesi V, Stojimirovi B. Treatment of insulin resistance in uremia. Int J Artif Organs. 2003;26(2):100–4.Google Scholar
  17. 17.
    Tonshoff B, Kiepe D, S C. Growth hormone/ insulin-like growth factor system in children with chronic renal failure. Pediatr Nephrol. 2005;20, 279–89.Google Scholar
  18. 18.
    Fortes PC, de Moraes TP, et al. Insulin resistance and glucose homeostasis in peritoneal dialysis. Perit Dial Int. 2009;29:S145–8.PubMedGoogle Scholar
  19. 19.
    Wada T, Miyata T, Kurokawa K. Implication of carbonyl stress in long-term uremic complications. Nephrol Dial Transplant. 1999;14(1):79–81.CrossRefPubMedGoogle Scholar
  20. 20.
    Lim VS. Thyroid function in patients with chronic renal failure. Am J Kid Dis. 2001;38(1):80–4.CrossRefGoogle Scholar
  21. 21.
    Lin C, Chen TW, Ng YY, Chou YH, WC Y. Thyroid dysfunction and nodular goiter in hemodialysis and peritoneal dialysis patients. Perit Dial Int. 1998;18:516–21.Google Scholar
  22. 22.
    Dulau IA, Popescu G, et al. Thyroid hormones clearance through the dialysis membrane determines a higher incidence of thyroid disease in patients on maintenance hemodialysis (abstract). Nephrol Dial Transplant. 2000;15(9):A149.CrossRefGoogle Scholar
  23. 23.
    Yonemura K, Nakajima T, et al. Low free thyroxine concentrations and deficient nocturnal surge of thyroid-stimulating hormone in haemodialysed patients compared with undialysed patients. Nephrol Dial Transplant. 2000;15(5):668–72.CrossRefPubMedGoogle Scholar
  24. 24.
    Stouthard JM, van der PT, et al. Effects of acute and chronic interleukin-6 administration on thyroid hormone metabolism in humans. J Clin Endocrinol Metab. 1994;79:1342–6.Google Scholar
  25. 25.
    Liu YY, Schultz JJ, Brent GA. A thyroid hormone receptor gene mutation (P398H) is associated with visceral adiposity and impaired catecholamine-stimulated lipolysis in mice. J Biol Chem. 2003;278:38913–20.CrossRefPubMedGoogle Scholar
  26. 26.
    Fernández-Real JM, López-Bermejo A, Castro A, Casamitjana R, Ricart W. Thyroid function is intrinsically linked to insulin sensitivity and endothelium-dependent vasodilation in healthy euthyroid subjects. J Clin Endocrinol Metab. 2006;91(9):3337–43.CrossRefPubMedGoogle Scholar
  27. 27.
    Malavazos AE, Cereda E, et al. Thyroid function and body weight: should we also consider the interplay with insulin resistance and fat distribution. Arch Intern Med. 2008;168:2284–5.CrossRefPubMedGoogle Scholar
  28. 28.
    Kumar HK, Yadav RK, et al. Association between thyroid hormones, insulin resistance, and metabolic syndrome. Saudi Med J. 2009;30(7):907–11.PubMedGoogle Scholar
  29. 29.
    Jameson JL. Mechanisms of thyroid hormone action. Philadelphia: WB Saunders; 2001.Google Scholar
  30. 30.
    Dimitriadis G, Mitrou P, et al. Insulin action in adipose tissue and muscle in hypothyroidism. J Clin Endocrinol Metab. 2006;91:4930–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Bakker SJ, ter Maaten JC, et al. The relationship between thyrotropin and low density lipoprotein cholesterol is modified by insulin sensitivity in healthy euthyroid subjects. J Clin Endocrinol Metab. 2001;86:1206–11.CrossRefPubMedGoogle Scholar
  32. 32.
    Amati F, Dubé JJ, Stefanovic-Racic M, Toledo FG, Goodpaster BH. Improvements in insulin sensitivity are blunted by subclinical hypothyroidism. Med Sci Sports Exerc. 2009;41(2):265–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Loeb JN. Catecholamines and the sympathoadrenal system in thyrotoxicosis. Philadelphia: Lippincott; 1996.Google Scholar
  34. 34.
    Chubb SA, Davis WA, Davis TM. Interactions among thyroid function, insulin sensitivity, and serum lipid concentrations: the Fremantle diabetes study. J Clin Endocrinol Metab. 2005;90:5317–20.CrossRefPubMedGoogle Scholar
  35. 35.
    Koritschoner NP, Alvarez-Dolado M, et al. Thyroid hormone regulates the obesity gene tub. EMBO Rep. 2001;2:499–504.PubMedGoogle Scholar
  36. 36.
    Levine JA, Nygren J, Short KR, Nair KS. Effect of hyperthyroidism on spontaneous physical activity and energy expenditure in rats. J Appl Physiol. 2003;94:165–70.PubMedGoogle Scholar
  37. 37.
    Wang H, Chu WS, et al. Uncoupling protein-2 polymorphisms in type 2 diabetes, obesity, and insulin secretion. Am J Physiol Endocrinol Metab. 2004;286:E1–7.CrossRefPubMedGoogle Scholar
  38. 38.
    Cheng SC, Chu TS, et al. Association of hypertriglyceridemia and insulin resistance in uremic patients undergoing CAPD. Perit Dial Int. 2001;21:282–9.PubMedGoogle Scholar
  39. 39.
    Murase T, Cattran DC, Rubenstein B, Steiner G. Inhibition of lipoprotein lipase by uremic plasma, a possible cause of hypertriglyceridemia. Metabolism. 1975;24(11):1279–86.CrossRefPubMedGoogle Scholar
  40. 40.
    Lee SW, Park Geun Ho, et al. Insulin resistance and muscle wasting in non-diabetic end-stage renal disease patients. Nephrol Dial Transplant. 2007;22:2554–62.CrossRefPubMedGoogle Scholar
  41. 41.
    Szu-Chun H, Der-Cherng T. Adiposity and insulin resistance in nondiabetic hemodialysis patients: effects of high energy supplementation. Am J Clin Nutr. 2009;90:64–9.CrossRefGoogle Scholar
  42. 42.
    Hen JL. Insulin resistance and risk of chronic kidney disease in non diabetic US adults. J Am Soc Nephrol. 2003;14(2):469–77.CrossRefGoogle Scholar
  43. 43.
    AlZadjali MA, Godfrey V, et al. Insulin resistance is highly prevalent and is associated with reduced exercise tolerance in nondiabetic patients with heart failure. J Am Coll Cardiol. 2009;53(9):747–53.CrossRefPubMedGoogle Scholar
  44. 44.
    Rashid S, Patterson BW, Lewis GF. Thematic review series: patient-oriented research. What have we learned about HDL metabolism from kinetics studies in humans. J Lipid Res. 2006;47(1):631–1642.Google Scholar
  45. 45.
    Xiao C, Watanabe T, et al. Enhanced cellular uptake of remnant high-density lipoprotein particles: a mechanism for high-density lipoprotein lowering in insulin resistance and hypertriglyceridemia. Circ Res. 2008;103:159–66.CrossRefPubMedGoogle Scholar
  46. 46.
    Ben Ounis O, Elloumi M, et al. Effects of two-month physical-endurance and diet-restriction programmes on lipid profiles and insulin resistance in obese adolescent boys. Diabetes Metab. 2008;34(6 Pt 1):595–600.CrossRefPubMedGoogle Scholar
  47. 47.
    Laws A, Reaven GM. Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. J Intern Med. 1992;231(1):25–30.CrossRefPubMedGoogle Scholar
  48. 48.
    Borissova AM, Djambazova A, et al. Effect of erythropoietin on the metabolic and peripheral insulin sensitivity in diabetic patients on hemodialysis. Nephrol Dial Transplant. 1993;8:93–5.PubMedGoogle Scholar
  49. 49.
    Roos A, Bakker SJ, Links TP, Gans RO, Wolffenbuttel BH. Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. J Clin Endocrinol Metab. 2007;92:491–6.CrossRefPubMedGoogle Scholar
  50. 50.
    Kobayashi S, Maejima S, Ikeda T, Nagase M. Impact of dialysis therapy on insulin resistance in end-stage renal disease: comparison of haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 2000;15:65–70.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Internal Medicine and Nephrology, Faculty of MedicineAin Shams UniversityCairoEgypt
  2. 2.Clinical Pathology DepartmentAl Azhar UniversityCairoEgypt

Personalised recommendations